Mines D'Or Orbec Inc. (BLUE)
Jun 2, 2025 - BLUE was delisted (reason: acquired by Carlyle and SK Capital)
4.970
0.00 (0.00%)
Inactive · Last trade price
on May 30, 2025
bluebird bio Stock Forecast
BLUE's stock price has decreased by -72.49% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for bluebird bio stock had an average target of 44.6, with a low estimate of 5 and a high estimate of 120.
Price Target: $44.6 (+797.38%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
The average analyst rating for bluebird bio stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $40 → $8 | Buy | Maintains | $40 → $8 | +60.97% | Mar 31, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $40 → $5 | Hold | Maintains | $40 → $5 | +0.60% | Feb 24, 2025 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Feb 24, 2025 |
| Barclays | Barclays | Buy Maintains $2 → $40 | Buy | Maintains | $2 → $40 | +704.83% | Dec 31, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $80 | Hold | Reiterates | $80 | +1,509.66% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
255.99M
from 83.81M
Increased by 205.45%
Revenue Next Year
265.57M
from 255.99M
Increased by 3.74%
EPS This Year
-11.46
from -24.84
EPS Next Year
-10.73
from -11.46
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 403.0M | 296.1M | 445.7M | ||
| Avg | 256.0M | 265.6M | 357.8M | ||
| Low | 147.1M | 220.5M | 271.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 380.9% | 15.7% | 67.8% | ||
| Avg | 205.5% | 3.7% | 34.7% | ||
| Low | 75.5% | -13.9% | 2.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.68 | -5.25 | -3.20 | ||
| Avg | -11.46 | -10.73 | -6.84 | ||
| Low | -23.13 | -17.64 | -10.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.